Doctor of Dentistry Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jeffrey Hammoudeh

Plastic and Reconstructive Surgery Los Angeles, CA Doctor of Dentistry

NPI 1285715086 CMS profile 1167786

4650 W Sunset Blvd, Ms# 96, Los Angeles, CA 90027

Open in the dashboard

General payments

$159,423

190 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jeffrey Hammoudeh of Los Angeles, CA is reported in the CMS Open Payments database as having received $159,423 across 190 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Plastic and Reconstructive Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $89,596 119
2024 General $10,349 17
2023 General $10,320 15
2022 General $13,856 10
2021 General $11,388 13
2020 General $17,941 11
2019 General $5,974 5

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jeffrey Hammoudeh
  • Plastic and Reconstructive Surgery median
  • Middle half of Plastic and Reconstructive Surgery
  • National median

In program year 2025, general payments to Jeffrey Hammoudeh were reported at $89,596. Among 2,070 Plastic and Reconstructive Surgery profiles paid that year, the median was $442 and the middle half received between $150 and $1,242.

Show as a table
Year Jeffrey Hammoudeh Plastic and Reconstructive Surgery median Middle half National median
2019 $5,974 $335 $121–$1,264 $163
2020 $17,941 $162 $57–$417 $114
2021 $11,388 $245 $89–$735 $132
2022 $13,856 $325 $120–$932 $149
2023 $10,320 $343 $129–$999 $160
2024 $10,349 $390 $141–$1,085 $164
2025 $89,596 $442 $150–$1,242 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. KLS-Martin L.P. $158,743 178 payments
  2. Stryker Corporation $455 7 payments
  3. Allergan Inc. $96 1 payment
  4. Zimvie Inc. $47 2 payments
  5. DePuy Synthes Sales Inc. $46 1 payment
  6. Straumann USA LLC $37 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Long term medical supply or device loan $77,235 102 payments
  2. Royalty or License $77,009 47 payments
  3. Food and Beverage $2,490 36 payments
  4. Gift $1,743 1 payment
  5. Debt forgiveness $946 4 payments
Products named General payments · program years 2019–2025
  1. CMF Osteosynthesis $9,696 5 payments
  2. CMF Distraction & Tissue Molding $6,135 3 payments
  3. IPS $3,627 4 payments
  4. LEVEL ONE CMF,PLATE, RECON, TLTS, STR, 2.7 MM SCREW,20 HOLE, 160 MM, T=3.0 MM,CP TITANIUM,QTY:001 EA $2,817 1 payment
  5. LEVEL ONE CMF,PLATE, RECON, TLTS, ANGLE TO ANGLE, 2.7 MM SCREW,32 HOLE, 227 MM, T=3.0 MM,CP TITANIUM,QTY:001 EA $2,412 1 payment
  6. LEVEL ONE CMF,PLATE, RECON, TLTS, ANGLE, RIGHT, 2.7 MM SCREW,26 HOLE, 193 MM, T=3.0 MM,CP TITANIUM,QTY:001 EA $2,172 1 payment
  7. LEVEL ONE CMF,PLATE, RECON, TLTS, ANGLE, LEFT, 2.7 MM SCREW,26 HOLE, 193 MM, T=3.0 MM,CP TITANIUM,QTY:001 EA $2,172 1 payment
  8. LEVEL ONE CMF,PLATE, RECON, TLTS, ANGLE TO ANGLE, 2.0-2.5 MM SCREW,32 HOLE, 222 MM, T=2.0 MM,CP TITANIUM,QTY:001 EA $2,080 1 payment
  9. LEVEL ONE CMF,PLATE, FRACTURE, TLTS, ANGLE, 2.0-2.5 MM SCREW,8 HOLE, T=1.5 MM,TI-6AL-4V,QTY:001 EA $1,841 1 payment
  10. LEVEL ONE CMF,PLATE, FRACTURE, TLTS, ANGLE, 2.0-2.5 MM SCREW,6 HOLE, T=1.5 MM,TI-6AL-4V,QTY:001 EA $1,815 1 payment
  11. Other $63,713 112 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

72

Median for Pediatric Medicine: 38

Drug cost

$341

Median for Pediatric Medicine: $2,769

Branded share of claims

0%

Median for Pediatric Medicine: 18.4%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Chlorhexidine Gluconate Generic 25 $172
Amoxicillin Generic 47 $169

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,361 Part D prescribers listed as Pediatric Medicine; they describe a distribution and say nothing about conduct.

Records

190 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Plastic and Reconstructive Surgery in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record